Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

NASDAQ:NMRA - US6409791000 - Common Stock

1.68 USD
+0.05 (+3.07%)
Last: 9/5/2025, 8:00:02 PM
1.68 USD
0 (0%)
After Hours: 9/5/2025, 8:00:02 PM
Fundamental Rating

1

NMRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. NMRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NMRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NMRA had negative earnings in the past year.
NMRA had a negative operating cash flow in the past year.
In the past 5 years NMRA always reported negative net income.
In the past 5 years NMRA always reported negative operating cash flow.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of NMRA (-112.63%) is worse than 77.95% of its industry peers.
NMRA has a Return On Equity of -137.84%. This is in the lower half of the industry: NMRA underperforms 64.62% of its industry peers.
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

NMRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, NMRA has more shares outstanding
Compared to 5 years ago, NMRA has more shares outstanding
NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -5.51, we must say that NMRA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NMRA (-5.51) is worse than 60.00% of its industry peers.
NMRA has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
NMRA's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. NMRA outperforms 50.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

NMRA has a Current Ratio of 10.54. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
NMRA has a better Current ratio (10.54) than 83.08% of its industry peers.
NMRA has a Quick Ratio of 10.54. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
NMRA has a Quick ratio of 10.54. This is amongst the best in the industry. NMRA outperforms 83.08% of its industry peers.
Industry RankSector Rank
Current Ratio 10.54
Quick Ratio 10.54
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.67% over the past year.
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.76% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.62%
EPS Next 2Y13.39%
EPS Next 3Y9.51%
EPS Next 5Y13.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMRA. In the last year negative earnings were reported.
Also next year NMRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.39%
EPS Next 3Y9.51%

More info and screens

0

5. Dividend

5.1 Amount

NMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (9/5/2025, 8:00:02 PM)

After market: 1.68 0 (0%)

1.68

+0.05 (+3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners60.73%
Inst Owner Change-12.84%
Ins Owners5.42%
Ins Owner Change-0.03%
Market Cap272.08M
Analysts74.29
Price Target7.14 (325%)
Short Float %4.49%
Short Ratio3.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.08%
Min EPS beat(2)-10.01%
Max EPS beat(2)12.16%
EPS beat(4)2
Avg EPS beat(4)1.94%
Min EPS beat(4)-13.12%
Max EPS beat(4)18.71%
EPS beat(8)4
Avg EPS beat(8)-27.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.06%
EPS NQ rev (1m)6.27%
EPS NQ rev (3m)20.41%
EPS NY rev (1m)-0.52%
EPS NY rev (3m)5.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.49
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS1.13
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.54
Quick Ratio 10.54
Altman-Z -5.51
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
EPS Next Y5.62%
EPS Next 2Y13.39%
EPS Next 3Y9.51%
EPS Next 5Y13.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.9%
EBIT Next 3Y13.29%
EBIT Next 5Y7.21%
FCF growth 1Y-62.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.8%
OCF growth 3YN/A
OCF growth 5YN/A